| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f55b6b4f75a04c6c31da9ee6fc1208bf |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10T436-163333 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-38 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-38 |
| filingDate |
1980-08-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1511e714a074787dd05c2bbc78d94ae7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ae099c1f7544032b4079da76d612a47 |
| publicationDate |
1981-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-8100517-A1 |
| titleOfInvention |
Snake venom neurotoxin prophylaxis and therapy for poisonous organophosphates |
| abstract |
Method for treatment of animals exposed to or subject to exposure to organophosphate animal poisonous nerve agents. The animals are injected with an effective amount of modified neurotoxin, preferably intramuscularly or intravenously, either prior to or shortly after exposure to the nerve agents. Particularly when the injection is administered prior to exposure, and where the dosage is of a higher amount, certain compositions achieve 100% survivors of Rhesus monkeys, even in the face of a challenge of 5 LD50 of the nerve agent. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0063091-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0063091-A3 |
| priorityDate |
1979-08-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |